# A Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of L2-01 in Subjects With Crohn's Disease

> **NCT07010926** · PHASE2 · NOT_YET_RECRUITING · sponsor: **L2 Bio, LLC** · enrollment: 120 (estimated)

## Conditions studied

- Crohn&Amp;#39;s
- Crohn&Amp;#39;s Disease (CD)

## Interventions

- **BIOLOGICAL:** L2-01 adipose-derived mesenchymal stem cells (MSC)
- **OTHER:** Placebo saline solution

## Key facts

- **NCT ID:** NCT07010926
- **Lead sponsor:** L2 Bio, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07010926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07010926, "A Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of L2-01 in Subjects With Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07010926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*